All In Biotech

Drug Trial Radar · NCT04541589

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjögren's Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

206

Actual

Start

Jan 5, 2021

Primary completion

Aug 19, 2024

Study completion Aug 19, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525). Additionally, this Extension study will further explore the pharmacokinetics (PK) and efficacy of iscalimab at two dose level.

Conditions

  • Sjogren's Syndrome

Interventions

  • IscalimabDrug

    Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).

  • PlaceboOther

    Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to maintain blinding until the final database lock of the core study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of extension study up to 14 weeks after last study-drug administration or end of study (whichever occurred earlier), assessed up to approximately 60 weeks

Locations

62 sites in 23 countries. Site status is shown where the registry gives one.

  • North GA Rheumatology Group PC

    Suwanee, Georgia

  • Ochsner Health System

    Baton Rouge, Louisiana

  • The John Hopkins Jerome L Greene Sjogren

    Baltimore, Maryland

  • Tufts School of Dental Medicine

    Boston, Massachusetts

  • Winthrop University Hospital

    Mineola, New York

  • Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Uni Wisconsin School Med Pub Health

    Madison, Wisconsin

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Rimouski, Quebec, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, Canada

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Valdivia, Los Ríos Region, Chile

  • Novartis Investigative Site

    Santiago, RM, Chile

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Székesfehérvár, Fejér, Hungary

  • Novartis Investigative Site

    Haifa, Israel

  • Novartis Investigative Site

    Kfar Saba, Israel

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Pisa, PI, Italy

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.